http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012109392-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-738 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728 |
| filingDate | 2010-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012109392-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITION FOR REDUCING PAIN |
| abstract | 1. A pharmaceutical composition for alleviating pain in joint disease, comprising hyaluronic acid, which is crosslinked by cyclization of a double bond in the cinnamic acid group in the partially amidated hyaluronic acid represented by formula (1) to form cyclobutane cyclaglide Ar is an optionally substituted phenyl group, n is an integer of 2 or 3, HA is the carboxy residue of hyaluronic acid and m is the ratio of the amidation of hyaluronic acid to all carboxyl groups and m is equal to 3-50% relative to all the carboxyl groups; ifaretically acceptable carrier. 2. The pharmaceutical composition according to claim 1, in which the content of crosslinked hyaluronic acid is 0.5-3.0 wt.% Based on the total volume of the product. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is an injectable product. The pharmaceutical composition according to claim 3, wherein a single dosage of the product for injection is 2-3 ml. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is a single dose preparation. The pharmaceutical composition according to claim 5, wherein the preparation is administered at one time with an administration interval of 13 weeks or longer. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is used for long-term action for at least 13 weeks. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is used for long-term action, at least up to 26 weeks. The pharmaceutical composition according to claim 3, where the product for injection is a single-dose preparation, a single dosage of the product |
| priorityDate | 2009-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.